Disruptive Technology Content Hub Some ARKG Components Could Lead in Genetic Testing By Tom LydonJune 1, 2022
Disruptive Technology Content Hub Why Investors Should Consider ETFs That Target Innovation Platforms By Max ChenApril 27, 2022
Disruptive Technology Content Hub Refining Your Innovation Exposure: How to Access Tomorrow’s Opportunities By Max ChenApril 26, 2022
Disruptive Technology Content Hub One of ARK Invest’s Favorite Stocks Offers Big Rebound Potential By Tom LydonApril 8, 2022
Disruptive Technology Content Hub Disruptive Tech ETFs Rally on Encouraging Dialogue Between Russia and Ukraine By Max ChenMarch 29, 2022
Disruptive Technology Content Hub Teladoc Endorsement Could Be Positive for This ETF By Tom LydonFebruary 14, 2022
Disruptive Technology Content Hub Volatility Is Not a Bad Word With a Long-Term Time Horizon By Max ChenFebruary 4, 2022
Disruptive Technology Content Hub A Bright Outlook for Gene Editing Investing By Tom LydonFebruary 2, 2022
Disruptive Technology Content Hub Gene Editing Stocks Might Be Building Some Momentum By Tom LydonJanuary 12, 2022
Disruptive Technology Content Hub Pfizer/Beam Deal Highlights In Vivo Potential By Tom LydonJanuary 11, 2022
Disruptive Technology Content Hub Genomics Could Make Inroads in Prenatal Testing By Tom LydonDecember 22, 2021
Disruptive Technology Content Hub Unusual Sequencing Could Be Predictive in Coronavirus Fight By Tom LydonDecember 14, 2021
Disruptive Technology Content Hub Omicron Variant Shows Need to Expand Genomics Capabilities By Tom LydonDecember 6, 2021
Disruptive Technology Content Hub Opportunity Could Be Knocking for Disruptive Healthcare Strategies By Tom LydonNovember 23, 2021
Disruptive Technology Content Hub Some Value Available in High Octane Healthcare ETF By Tom LydonNovember 18, 2021
